HHH vs NHI
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HHH exhibits a stable but weak Piotroski F-Score of 4/9, reflecting mediocre financial health. The company is facing a severe fundamental crisis with YoY revenue declining by 36.5% and earnings collapsing by 96.9%. While the stock trades near its book value (P/B 0.99), there is a massive disconnect between the current price ($63.79) and the growth-based intrinsic value ($15.47). Bearish technical trends and insider selling further compound the negative outlook despite optimistic analyst price targets.
NHI exhibits a precarious fundamental profile, anchored by a Piotroski F-Score of 4/9, which indicates only marginal stability. The stock is trading at a severe premium to both its Graham Number ($46.26) and its growth-based Intrinsic Value ($21.14), suggesting significant overvaluation. Most concerning is the dividend payout ratio of 120.53%, indicating that the current dividend is unsustainable and not covered by earnings. With negative YoY revenue and earnings growth and a 0/100 technical trend, the data suggests a high risk of price correction.
Compare Another Pair
Related Comparisons
HHH vs NHI: Head-to-Head Comparison
This page compares Howard Hughes Holdings Inc. (HHH) and National Health Investors, Inc. (NHI) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.